Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

hankook korus pharm co. - cefepime (cefepime hydrochloride) - powder for solution for injection - 1000mg

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cefepime, quantity: 1000 mg - injection, powder for - excipient ingredients: arginine - adults: cefepime is indicated in the treatment of the infections listed below when caused by susceptible bacteria.. - lower respiratory tract infections, including pneumonia and bronchitis. - urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections. - skin and skin structure infections. intra-abdominal infections, including peritonitis and biliary tract infections. - gynaecological infections. septicaemia. - empirical treatment in febrile neutropenic patients (see precautions). cefepime is also indicated for surgical prophylaxis in patients undergoing intra-abdominal surgery. in this indication it is essential that metronidazole also be administered. paediatrics: cefepime is indicated in paediatric patients over 2 months of age for the treatment of the infections listed below when caused by susceptible bacteria. pneumonia. - urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections. - skin and skin structure infections. - septicaemia. - empirical treatment in febrile neutropenic patients (see precautions). culture and susceptibility studies should be performed when appropriate to determine susceptibility of the causative organism(s) to cefepime. empirical therapy with cefepime may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. because of its broad spectrum of bactericidal activity against gram positive and gram negative bacteria, cefepime can be used appropriately as monotherapy prior to identification of the causative organisms(s). in the treatment of febrile neutropenia, consideration should be given to the need for other antibiotics in combination with cefepime. in patients who are at risk of mixed aerobic/ anaerobic infection, including infections in which bacterioides fragilis may be present, concurrent initial therapy with an antianaerobic agent is recommended before the causative organism(s) is known.

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - cefepime -

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - cefepime -

United States - English - NLM (National Library of Medicine)

b. braun medical inc. - cefepime hydrochloride (unii: i8x1o0607p) (cefepime - unii:807pw4vqe3) - cefepime 1 g in 50 ml - cefepime for injection and dextrose injection is indicated for the treatment of pneumonia (moderate to severe) caused by streptococcus pneumoniae (including cases associated with concurrent bacteremia), pseudomonas aeruginosa , klebsiella pneumoniae , or enterobacter species. cefepime for injection and dextrose injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. in patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. insufficient data exist to support the efficacy of cefepime monotherapy in such patients [see clinical studies (14.1)]. cefepime for injection and dextrose injection is indicated for uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by escherichia coli or klebsiella pneumoniae when the

United States - English - NLM (National Library of Medicine)

sandoz inc - cefepime hydrochloride (unii: i8x1o0607p) (cefepime - unii:807pw4vqe3) - cefepime 1 g - cefepime for injection, usp is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also precautions: pediatric use and dosage and administration ): pneumonia (moderate to severe) caused by streptococcus pneumoniae , including cases associated with concurrent bacteremia, pseudomonas aeruginosa , klebsiella pneumoniae , or enterobacter species. empiric therapy for febrile neutropenic patients. cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. in patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (see clinical studies .) uncomplicated and complicated urinary tract infection

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - cefepime hydrochloride (unii: i8x1o0607p) (cefepime - unii:807pw4vqe3) - cefepime 1 g in 50 ml - cefepime injection is indicated for pneumonia (moderate to severe) caused by streptococcus pneumoniae, including cases associated with concurrent bacteremia, pseudomonas aeruginosa, klebsiella pneumoniae, or enterobacter species. cefepime injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. in patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. insufficient data exist to support the efficacy of cefepime monotherapy in such patients [see clinical studies (14)]. cefepime injection is indicated for uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by escherichia coli or klebsiella pneumoniae, when the infection is severe, or caused by escherichia coli, klebsiella pneumoniae, or proteus mirabilis, w

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - cefepime dihydrochloride monohydrate 595mg equivalent to cefepime 500 mg - powder for injection - 500 mg - active: cefepime dihydrochloride monohydrate 595mg equivalent to cefepime 500 mg excipient: arginine - adults: cefepime-aft is indicated for the treatment of the indications listed below when caused by susceptible bacteria: · lower respiratory tract infections, including pneumonia and bronchitis · urinary tract infections , both complicated, including pyelonephritis, and uncomplicated infections · skin and skin structure infections · intra-abdominal infections, including peritonitis and biliary tract infections · septicaemia · empiric treatment in febrile neutropenic patients.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - cefepime hydrochloride (unii: i8x1o0607p) (cefepime - unii:807pw4vqe3) - cefepime 1 g - cefepime for injection is indicated in the treatment of pneumonia (moderate to severe) caused by susceptible strains of streptococcus pneumoniae , including cases associated with concurrent bacteremia, pseudomonas aeruginosa , klebsiella pneumoniae , or enterobacter species. cefepime for injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. in patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. insufficient data exist to support the efficacy of cefepime monotherapy in such patients [see clinical studies ( 14.1)] . cefepime for injection is indicated in the treatment of uncomplicated and complicated urinary tract infections (including p

United States - English - NLM (National Library of Medicine)

apotex corporation - cefepime hydrochloride (unii: i8x1o0607p) (cefepime - unii:807pw4vqe3) - cefepime 1 g - cefepime for injection is indicated in the treatment of pneumonia (moderate to severe) caused by susceptible strains of streptococcus pneumoniae , including cases associated with concurrent bacteremia, pseudomonas aeruginosa , klebsiella pneumoniae , or enterobacter species. cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. in patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. insufficient data exist to support the efficacy of cefepime monotherapy in such patients [see clinical studies (14.1)]. cefepime is indicated in the treatment of uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by susceptible isolates of escherichia coli or klebsiella pneumoniae , when the infection is severe, or caused by